ClinicalTrials.gg
CompletedNCT02330276EpicatechinUpdated Apr 17, 2017Results posted

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

A Phase 1 interventional study of (+)-Epicatechin in Pre-diabetes, sponsored by Veterans Medical Research Foundation. Completed at 1 site in United States. Open to participants aged 21 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Veterans Medical Research Foundation · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 350 studies in Glucose Intolerance with a site in United States — 43 open to participants now, 65 under way, none of them phase 3. Glucose Intolerance · United States.

Enrollment
271st of 307
12 · median 50
Started
2014
with 14 others
Phase 1
16 of 350
1 open now
Registered
145th of 350
by date

Among the 350 studies in Glucose Intolerance with a site in United States, this one is the 271st largest by enrollment of the 307 interventional ones that give a count, is one of 15 that started in 2014, is one of 16 in phase 1, and was the 145th registered.

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.

Browse Glucose Intolerance studies →

Open to participants now

43 of the 350 studies in Glucose Intolerance with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glucose Intolerance studies recruiting now, 13 (19%) set no upper age limit and 50 (74%) stop at 75 or younger; 9 take children under 18; 32 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 350 studies in Glucose Intolerance with a site in United States, or all of them as a file.
02

Study summary

Early Phase Pre-Clinical and Initial Clinical Research on (+)- Epicatechin.

Read the detailed description

This project is a double-blinded randomized Phase I study that will include dose-ranging one day PK and pharmacodynamic (PD) studies. Subjects will include healthy individuals and subjects who meet the American Diabetes Association (ADA) criteria for pre-diabetes, including IFG.

03

Conditions studied

  • Pre-diabetes

Browse trials for

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy or pre-diabetic based on medical history
  • Male or female
  • Must be 21 to 75 years of age (inclusive)
  • Able to give to the procedures
  • If female, must be either or test negative for pregnancy at screening and on the day of the procedure. Women on estrogen therapy will be included.
  • If of , must practice and be willing to continue to practice appropriate during the entire duration of the study
  • Medication use stable for 4 weeks
  • (BMI) > 27 kg/m\^2
  • Definition of pre-diabetes: impaired fasting glucose (IFG, fasting glucose = 100-125 mg/dL) and elevated (5.7-6.4%), each in the absence of other risk factors for diabetes

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes
  • Pregnancy
  • Younger than 21 or older than 75 years of age
  • abnormalities in liver or kidney function (>3x ), determined in the last 6 months by a certified clinical laboratory
  • Recent MI or stroke (within 6 months of screening)
  • Blood pressure (BP) >160 mmHg Systolic and >100 mmHg Diastolic
  • Medications - thiazolidinediones, any , anti-depressants, weight loss drugs
  • Other diseases, besides type 2 diabetes, influencing carbohydrate metabolism
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    10 mg (+)-epicatechin

    4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally

    Drug: (+)-Epicatechin

  • Experimental
    30 mg (+)-epicatechin

    4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally

    Drug: (+)-Epicatechin

  • Experimental
    100 mg (+)-epicatechin

    4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally

    Drug: (+)-Epicatechin

Interventions

  • Drug(+)-Epicatechin

    Drug page: (+)-epicatechinStudies of (+)-epicatechin(+)-epicatechin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.

    Also known as: Epicatechin

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites

    This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers

    Time frame: Baseline and 24 hours

Secondary outcomes

  1. Change From Baseline in Major Safety Endpoints

    Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (\>1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (\>1.5 ULN).

    Time frame: Baseline and 24 hours

  2. Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)

    Time frame: Baseline and 24 hours

  3. Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)

    Time frame: Baseline and 24 hours

  4. Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)

    Time frame: Baseline and 24 hours

07

Results

Posted Apr 17, 2017

Participant flow

Participant flow — Overall Study
Milestone10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Started444
Completed444
Not completed000

Outcome measures

PrimaryChange From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites

This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers

Time frame:
Baseline and 24 hours
Reported as:
Mean · nM*hr
Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites
nM*hr10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Metabolites (AUC nM*hr)105.8 ± 122.2132.7 ± 148.0162.3 ± 209.8
epicatechin-sulfate (AUC nM*hr)291.3 ± 119.21639 ± 389.03031 ± 1543
epicatechin-glucuronide (AUC nM*hr)3.375 ± 2.48847.18 ± 39.41398.3 ± 292.7
Methyl-epi-sulfate (AUC nM*hr)457.8 ± 211.53190 ± 496.616699 ± 7218
Total parent compound and metabolites (AUC nM*hr)840.3 ± 311.14996 ± 570.022563 ± 10335
Statistical analysis
  • 10 mg (+)-Epicatechin vs 30 mg (+)-Epicatechin vs 100 mg (+)-Epicatechin · General linear mixed-effects models · p = 0.05 (The reported P-Value was calculated)
SecondaryChange From Baseline in Major Safety Endpoints

Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (\>1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (\>1.5 ULN).

Time frame:
Baseline and 24 hours
Reported as:
Number · participants
Change From Baseline in Major Safety Endpoints
participants10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Change From Baseline in Major Safety Endpoints000
Statistical analysis
  • 10 mg (+)-Epicatechin vs 30 mg (+)-Epicatechin vs 100 mg (+)-Epicatechin · ANOVA · p = <0.05 (for change in heart rate at 24 hr post-dosing from baseline between the 3 doses) · Mean difference (final values): 77.9 · 95% CI 70.3 to 85.5
SecondaryChange From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)
Time frame:
Baseline and 24 hours
Reported as:
Mean · mg/dL*24hr
Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)
mg/dL*24hr10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)368.3 ± 158.5342.6 ± 193.5513.4 ± 185.6
Statistical analysis
  • 10 mg (+)-Epicatechin vs 30 mg (+)-Epicatechin vs 100 mg (+)-Epicatechin · General linear mixed-effects models · p = 0.05 (The reported P-Value was calculated)
SecondaryChange From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)
Time frame:
Baseline and 24 hours
Reported as:
Mean · uU/mL*24 hr
Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)
uU/mL*24 hr10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)1192 ± 488.5707.2 ± 211.51334 ± 666.5
Statistical analysis
  • 10 mg (+)-Epicatechin vs 30 mg (+)-Epicatechin vs 100 mg (+)-Epicatechin · General linear mixed-effects models · p = 0.05 (The reported P-Value was calculated)
SecondaryChange From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)
Time frame:
Baseline and 24 hours
Reported as:
Mean · ng/mL*24hr
Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)
ng/mL*24hr10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)61.74 ± 27.6457.56 ± 28.5664.23 ± 27.11
Statistical analysis
  • 10 mg (+)-Epicatechin vs 30 mg (+)-Epicatechin vs 100 mg (+)-Epicatechin · General linear mixed-effects models · p = 0.05 (The reported P-Value was calculated)

Adverse events

Collected over 9 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg (+)-Epicatechin—0/4 (0%)0/4 (0%)
30 mg (+)-Epicatechin—0/4 (0%)0/4 (0%)
100 mg (+)-Epicatechin—0/4 (0%)1/4 (25%)
Most frequent other events
Most frequent other events
Event10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-Epicatechin
Intermittent HeadachesNervous system disorders0/40/41/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-EpicatechinTotal
<=18 years0000
Between 18 and 65 years3407
>=65 years1045
Sex: Female, Male
Sex: Female, Male(Participants)10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-EpicatechinTotal
Female1214
Male3238
Race (NIH/OMB)
Race (NIH/OMB)(Participants)10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-EpicatechinTotal
American Indian or Alaska Native1001
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American3003
White0448
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)10 mg (+)-Epicatechin30 mg (+)-Epicatechin100 mg (+)-EpicatechinTotal
United States44412
08

Study locations

1 site
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2014
First posted
Jan 1, 2015
Start
Sep 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Apr 17, 2017
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02330276
Lead sponsor
Veterans Medical Research Foundation
Responsible party
Robert R. Henry, MD (Chief, Section of Diabetes, Endocrinology and Metabolism, Veterans Medical Research Foundation) — Principal investigator
First posted
Jan 1, 2015
Start date
Sep 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Apr 17, 2017
Last update
Apr 17, 2017

Study contacts

Robert R Henry, MD
principal investigator · San Diego Veterans Healthcare System

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: (+)-epicatechin

Start the discussion